Can Immunotherapy Play a Role in Pancreatic Ductal Adenocarcinoma?


A combination of  durvalumab and tremelimumab was tested on patients with metastatic pancreatic ductal adenocarcinoma.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Source Type: news

Related Links:

Advancing treatments for complex and deadly diseases needs gene signatures to identify patients at risk under various genetic and clinical conditions. Our new prognosis gene signature for lung adenocarcinoma meets that need with risk ‐stratification ability on mutation status ofEGFR andTP53, levels of immune checkpointPD ‐L1 expression, and with and without adjuvant chemotherapy. This is a helpful step toward selecting an effective, personalized treatment plan for lung adenocarcinoma patients. AbstractThe overall survival rates for lung cancer remain unsatisfactorily low, even for patients with biomarkers for which tar…

Source: Cancer MedicineCategory: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research

De Summa

Non-small-cell lung cancer, histologically classified into adenocarcinoma (AD) and squamous cell carcinoma, is one of the most deadly malignancies worldwide. Lung AD (LUAD) could benefit of a plethora of target therapies and, in the last few years, also of immunotherapies. Here we focused on a real-life cohort of LUAD and The Cancer Genome Atlas (TCGA)-LUAD dataset aiming to gain insights into the immune contexture of such a malignancy. We explored the mutational status of 41 genes and the expression of 94 genes, related to immune-checkpoint, inflammation, and stromal microenvironment. Surprisi…

Source: CancersCategory: Cancer & Oncology Authors: Tags: Article Source Type: research

Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second most common cause of cancer-related death in the United States by 2030. So far surgery remains the only curative option for pancreatic cancer, but fewer than 20% of patients have surgically resectable disease. Furthermore, pancreatic cancer exhibits a remarkable resistance to established therapeutic options, including chemotherapy, radiotherapy, and targeted therapy, because pancreatic cancer exhibits numerous mechanisms of resistance like genetic and epigenetic alterations and a complex and dense tumor microenvironment. The tumor m…

Source: Mol Biol CellCategory: Molecular Biology Authors: Tags: Prog Mol Biol Transl Sci Source Type: research

Conclusions: Hypofractionated carbon-ion RT showed excellent local control and overall survival without severe toxicities in lung cancer patients with isolated lymph node metastasis after surgery or carbon-ion RT for primary lung tumors. A multi-institutional prospective study is required to establish the efficacy and safety of carbon-ion RT.

Primary retroperitoneal serous adenocarcinoma (PRSA) is an extremely uncommon malignancy exclusively reported in females. Due to the rarity of the disease, it is difficult to establish a standardized treatment.

Source: BMC CancerCategory: Cancer & Oncology Authors: Tags: Case report Source Type: research

Pancreatic ductal adenocarcinoma is projected to become the second leading cause of cancer-related death and is largely resistant to immunotherapies. The tumor microenvironment, largely composed of heterogeneous myeloid cells, creates a physical, metabolic, and immunosuppressive barrier that prevents T cells from infiltrating cancer beds. In this issue of the JCI, Markosyan and colleagues have reported a tumor-intrinsic mechanism that excludes T cells from the vicinity of tumor cells. They showed that a receptor tyrosine kinase, ephrin-A receptor 2 (EPHA2), regulates prostaglandin endoperoxide synthase 2 (PTGS2) (encodes C…

Resistance to immunotherapy is one of the biggest problems of current oncotherapeutics. While T cell abundance is essential for tumor responsiveness to immunotherapy, factors that define the T cell–inflamed tumor microenvironment are not fully understood. We used an unbiased approach to identify tumor-intrinsic mechanisms shaping the immune tumor microenvironment (TME), focusing on pancreatic adenocarcinoma because it is refractory to immunotherapy and excludes T cells from the TME. From human tumors, we identified ephrin-A receptor 2 (EPHA2) as a candidate tumor-intrinsic driver of immunosuppression. Epha2 deletion …

Source: Journal of Clinical InvestigationCategory: Biomedical Science Authors: Source Type: research

Conditions:   Fallopian Tube Carcinosarcoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Germline BRCA1 Gene Mutation;   Germline BRCA2 Gene Mutation;   High Grade Fallopian Tube Serous A denocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Tumor;   Ovarian Seromucinous Carcinoma;   Ovaria…

AbstractMonoclonal antibodies targeting PD-1 are used for treating NSCLC. To date, proprotein convertase subtilisin/kexin type 9 (PCSK9) has been poorly investigated in the oncologic field. Here, we aimed at evaluating whether serum PCSK9 might represent a predictive factor for OS in older patients with advanced NSCLC under nivolumab treatment. Among 78 patients with advanced, pre-treated NSCLC previously enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 44 patients have been included in this sub-analysis due to the availability of serum samples for the measurement of PCSK9. Before each …

No immunotherapy strategy is yet offering consistent results against Pancreatic ductal adenocarcinoma (PDAC). A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.
PMID: 31315885 [PubMed – as supplied by publisher]

Source: Clinical Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

Source link